Sign in Create account

GENPHARMASEC LIMITED

Services · Commercial Services & Supplies

BSE: 531592
₹1.12
▲ 0.00 (0.00%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
63/100
Moderate
Valuation
97/100
Undervalued
Momentum
48/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹62 Cr
PE (TTM)
12.4
Industry median 24.9 (183 companies)
Price to Book
0.9
PEG (TTM)
0.2
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-50.7
Free Cash Flow
₹-18 Cr
as of March 31, 2026
Industry median ₹-0 Cr (372 companies)
EPS Growth (YoY)
0.00%
as of June 30, 2026
Industry median 0.00% (300 companies)
Net Profit Growth (TTM)
36.20%
as of June 30, 2026
Industry median 0.00% (325 companies)
Operating Revenue Growth (TTM)
312.37%
as of June 30, 2026
Industry median 0.00% (317 companies)
Profit Growth (YoY)
-18.24%
as of Sept. 30, 2025
Industry median 2.13% (293 companies)
Revenue Growth (YoY)
269.72%
as of June 30, 2026
Industry median 7.61% (227 companies)
Current Ratio
1.71
as of March 31, 2026
Industry median 2.48 (345 companies)
Debt to Equity
0.50
as of March 31, 2026
Industry median 0.06 (315 companies)
Interest Coverage
11.60
as of June 30, 2026
Industry median 2.71 (293 companies)
Net Margin
4.49%
as of March 31, 2026
Industry median 3.80% (247 companies)
Operating Margin (EBIT)
4.97%
as of June 30, 2026
Industry median 6.24% (257 companies)
Operating Margin (TTM)
4.56%
as of June 30, 2026
Industry median 4.63% (310 companies)
Return on Assets
5.29%
as of March 31, 2026
Industry median 0.99% (329 companies)
Return on Capital Employed
9.22%
as of March 31, 2026
Industry median 2.68% (300 companies)
Return on Equity
8.14%
as of March 31, 2026
Industry median 2.11% (328 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (0.50)
  • No Return on equity is 15% or more (8.1%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.0%
Low 1.1100 · High 1.1500
1W return
-1.8%
Low 1.1000 · High 1.1700
1M return
-0.9%
Low 1.0900 · High 1.3600
52W return
-65.6%
Low 0.9000 · High 1.3600
Lifetime High ₹156.0500 (March 29, 2019)
Lifetime Low ₹0.9900 (Aug. 17, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
1.1
10D
1.1
20D
1.2
50D
1.4
100D
1.9
200D
3.2

Delivery and volume

Day avg. delivery
90.5%
Week avg. delivery
84.4%
Month avg. delivery
78.1%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1.13
Pivot
First resistance1.14
Second resistance1.17
Third resistance1.18
First support1.10
Second support1.09
Third support1.06
Day RSI42.8
Day MFI56.7
Day MACD-0.05
Day MACD signal-0.06

Beta

1M1.89
3M1.17
1Y1.17
3Y0.70

Price change analysis

↓ -0.9%
Over 1 Month
LowHigh
1.091.36
↓ -65.6%
Over 3 Months
LowHigh
0.901.36
↓ -65.6%
Over 6 Months
LowHigh
0.901.36
↓ -65.6%
Over 1 Year
LowHigh
0.901.36
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 12.4 (own history: 36.2–81.5)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹45 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.0300

Ranks #119 of 315 in Commercial Services & Supplies by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter29.98%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 29.98% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 80 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
31 Aug 2026 RAJESH MIRCHUMAL SADHWANI Bulk Buy 4,000,000 1.0500 BSE
28 Aug 2026 RAJESH MIRCHUMAL SADHWANI Bulk Buy 5,000,000 1.0100 BSE
30 Dec 2024 DIVYA DEVEN PATHAK Bulk Sell 3,500,000 2.9500 BSE
4 Sep 2024 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Sell 2,857,581 3.3100 BSE
3 Sep 2024 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Sell 931,149 3.2700 BSE
3 Sep 2024 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Buy 3,057,693 3.1800 BSE
30 Aug 2024 MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Buy 3,400,003 3.7800 BSE
30 Aug 2024 ISHAAN TRADEFIN LLP Bulk Sell 4,500,000 3.8700 BSE
30 Aug 2024 ISHAAN TRADEFIN LLP Bulk Buy 4,500,000 3.7100 BSE
27 Aug 2024 STALLION WEALTH MANAGEMENT LLP Bulk Sell 1,350,000 3.3100 BSE

All bulk and block deals →

Corporate Actions

Full history (2 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Adi Rasayan Ltd. to GENERIC PHARMASEC LIMITED
—NAME_CHANGEName changed from GENERIC PHARMASEC LIMITED to GENPHARMASEC LIMITED

All corporate actions →

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 AGM/EGM Genpharmasec Ltd - 531592 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 AGM/EGM Genpharmasec Ltd - 531592 - Shareholder Meeting / Postal Ballot-Outcome of AGM
8 Sep 2026 Company Update Genpharmasec Ltd - 531592 - Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Sep 2026 Board Meeting Genpharmasec Ltd - 531592 - Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Wednesday, 02Nd September, 2026.
2 Sep 2026 Corp. Action Genpharmasec Ltd - 531592 - Intimation Of Book Closure For The Purpose Of AGM
2 Sep 2026 Insider Trading / SAST Genpharmasec Ltd - 531592 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Comfortable interest coverage (11.6x)
  • Healthy liquidity (Current Ratio 1.71)
  • Strong revenue growth YoY (269.7%)

Weaknesses

  • Low Return on Equity (8.1%)
  • Thin net profit margin (4.5%)
  • Declining profit YoY (-18.2%)

Opportunities

  • PEG below 1 (0.25) -- earnings growth outpacing its own valuation
  • PE below 15 (12.4) relative to a typical growth business
  • Trading below book value (PB 0.94)

Threats

  • Down 65.6% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about GENPHARMASEC LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.